Tuesday, March 17, 2026

What Does Michael DeSombre’s Visit Mean for U.S.-Korea Relations? Insights and Implications

U.S. Assistant Secretary Michael DeSombre visits South Korea to discuss U.S.-Korea alliance, North Korea negotiations, and defense strategies.

North Korean Hackers Target Defense Companies as Fake Recruiters

A North Korean hacking organization reportedly attempted to hack defense companies worldwide by disguising themselves as recruiters.

Hyundai Motor Company’s Elantra Tops 4 Million U.S. Sales—How a $22,000 Sedan Survived the SUV Era

Hyundai's Elantra surpasses 4 million sales in the U.S., showcasing strong value and diverse models in a competitive market.

Tag: Oncology

North KoreaKoreaKimMilitarySouth KoreaAIrelationsmarketInternational

Verismo Therapeutics Welcomes FDA Approval Expert Dennis Williams: What This Means for CAR-T Cell Therapy

HLB Innovation appoints Dr. Dennis Williams as VP of Regulatory Affairs at Verismo Therapeutics to enhance global regulatory strategies.

SK Biopharm’s 2026 Sales Meeting: Key Strategies for Senolamate’s Global Success

SK Biopharm's U.S. subsidiary held its annual sales meeting, focusing on growth strategies and collaboration for Cenobamate's success.

Hanmi Posts Record $1.16B Sales and $193M Operating Profit: What’s Driving the 2025 Surge

Hanmi Pharmaceutical reports record sales of $1.16 billion in January 2025, with significant growth in profits and new product launches.

HLB’s Liragratinib: A Game-Changer in Cholangiocarcinoma Treatment Revealed at ASCO GI 2026!

HLB's lirafugratinib shows promise as a precision oncology drug, targeting FGFR2 in cancer treatment. FDA application expected soon.

Big Pharma Braces for $300 Billion Loss as Blockbuster Drug Patents Expire

Global pharma faces $300B losses from patent expirations, prompting a shift to multi-indication drugs and innovative therapies.

J&J Aims to Treat Cancer Before It Starts Showing Symptoms

Johnson & Johnson leads in multiple myeloma treatment, pioneering early intervention for high-risk patients with a new subcutaneous formulation.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.